Literature DB >> 21058195

Antitumor effects of ursolic acid in a mouse model of postmenopausal breast cancer.

Rebecca E De Angel1, Sarah M Smith, Randolph D Glickman, Susan N Perkins, Stephen D Hursting.   

Abstract

Over the past two decades, bioactive natural compounds have been shown to be a plausible adjunct to the treatment of breast cancer, the second leading cause of cancer death among American women. This study was designed to investigate the effects of ursolic acid (UA), a pentacyclic triterpene found in many foods and herbs, in a model of postmenopausal breast cancer. Ovariectomized C57BL/6 mice (n = 40) were randomized to receive control diet (AIN-93G) or diet supplemented with UA at 1 of 3 doses (wt/wt): 0.05%, 0.10%, or 0.25% (≈54, 106, or 266 mg/kg body weight/day, respectively). After 3 wk, syngeneic MMTV-Wnt-1 mammary tumor cells were injected in the mammary fat pad, and mice continued on their respective diets for 5 more wk. All UA doses decreased tumor cell proliferation, as assessed by Ki67 immunostaining; nevertheless, UA at 0.10% was most effective in inhibiting tumor take and decreasing tumor final tumor size. Modulation of Akt/mTOR signaling and induction of apoptosis appeared to mediate these effects on tumor growth. UA potently disrupted cell cycle progression and induced necrosis in a clonal MMTV-Wnt-1 mammary tumor cell line in vitro. This study supports the potential of UA as an antitumorigenic agent.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 21058195     DOI: 10.1080/01635581.2010.492092

Source DB:  PubMed          Journal:  Nutr Cancer        ISSN: 0163-5581            Impact factor:   2.900


  30 in total

Review 1.  Cancer cell signaling pathways targeted by spice-derived nutraceuticals.

Authors:  Bokyung Sung; Sahdeo Prasad; Vivek R Yadav; Bharat B Aggarwal
Journal:  Nutr Cancer       Date:  2011-12-09       Impact factor: 2.900

Review 2.  Role of dietary fat on obesity-related postmenopausal breast cancer: insights from mouse models and methodological considerations.

Authors:  Pei Yee Tan; Kim Tiu Teng
Journal:  Breast Cancer       Date:  2021-03-09       Impact factor: 4.239

3.  Resveratrol and P-glycoprotein inhibitors enhance the anti-skin cancer effects of ursolic acid.

Authors:  Jacob J Junco; Anna Mancha; Gunjan Malik; Sung-Jen Wei; Dae Joon Kim; Huiyun Liang; Thomas J Slaga
Journal:  Mol Cancer Res       Date:  2013-09-26       Impact factor: 5.852

Review 4.  Therapeutic Potential of Ursolic Acid to Manage Neurodegenerative and Psychiatric Diseases.

Authors:  Ana B Ramos-Hryb; Francis L Pazini; Manuella P Kaster; Ana Lúcia S Rodrigues
Journal:  CNS Drugs       Date:  2017-12       Impact factor: 5.749

5.  3β-Hydroxy-urs-12-en-28-oic Acid Modulates Dietary Restriction Mediated Longevity and Ameliorates Toxic Protein Aggregation in C. elegans.

Authors:  Hema Negi; Shilpi Khare Saikia; Rakesh Pandey
Journal:  J Gerontol A Biol Sci Med Sci       Date:  2017-11-09       Impact factor: 6.053

Review 6.  Research progress of ursolic acid's anti-tumor actions.

Authors:  Li-li Zang; Bao-ning Wu; Yuan Lin; Jun Wang; Lei Fu; Ze-yao Tang
Journal:  Chin J Integr Med       Date:  2013-12-29       Impact factor: 1.978

Review 7.  Perspectives on natural compounds in chemoprevention and treatment of cancer: an update with new promising compounds.

Authors:  Abedul Haque; Daniel Brazeau; Arm R Amin
Journal:  Eur J Cancer       Date:  2021-04-14       Impact factor: 9.162

8.  Triterpenoid ursolic acid drives metabolic rewiring and epigenetic reprogramming in treatment/prevention of human prostate cancer.

Authors:  Shanyi Li; Renyi Wu; Lujing Wang; Hsiao-Chen Dina Kuo; Davit Sargsyan; Xi Zheng; Yujue Wang; Xiaoyang Su; Ah-Ng Kong
Journal:  Mol Carcinog       Date:  2021-11-02       Impact factor: 4.784

Review 9.  Nanoformulations of Ursolic Acid: A Modern Natural Anticancer Molecule.

Authors:  Longyun Wang; Qianqian Yin; Cun Liu; Ying Tang; Changgang Sun; Jing Zhuang
Journal:  Front Pharmacol       Date:  2021-07-05       Impact factor: 5.810

10.  Obesity, independent of p53 gene dosage, promotes mammary tumor progression and upregulates the p53 regulator microRNA-504.

Authors:  Nikki A Ford; Sarah M Dunlap; Karrie E Wheatley; Stephen D Hursting
Journal:  PLoS One       Date:  2013-06-28       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.